FEB 2-7 2003 E

INFORMATION DESCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO. APPLICATION NO. 002010-603 09/127,364

APPLICANT Yednock, et al. Filing Date GROUP July 31, 1998 1653

U.S. PATENT DOCUMENTS							
$\hat{}$	U.S. Patent C	ocument	sub				
Examiner Initials	Number	(if the last	Name of Patentee or Applicant Class of Cited Document	Date of Publication (MM-DD-YYYY)			
	4,018,913	514	20 Okamoto et al.	04-19-1977			
	4,018,915	514	Okamoto et al.	04-19-1977			
	4,036,955	514	20 Okamoto et al.	07-19-1977			
	4,041,156	514	Okamoto et al.	08-19-1977			
	4,046,876	514	Okamoto et al.	09-06-19			
	4,055,636	514	QO Okamoto et al.	10-25-19			
	4,055,651	514	319 Okamoto et al.	10-25-19			
	4,069,318	514	20 Okamoto et al.	01-17-19 🕳 💍			
	4,070,457	514	510 Okamoto et al.	01-24-1978			
	4,071,621	514	Q Okamoto et al.	01-31-197			
7	4,073,914	514	3/9 Kikumoto et al.	02-14-197			
	4,096,255	514	227, 5 Kikumoto et al.	06-20-1978			
XX	4,097,591	514	20 Okamoto et al.	06-27-1978			
ì	4,104,392	514	307 Okamoto et al.	08-01-1978			
	4,260,601	514	16 Reichelt	04-07-1981			
	4,804,676	514	423 Inaoka, et al.	02-14-1989			
	4,910,190	514	19 Bergeson, et al.	03-20-1990			
	4,977,168	514.	Bernat et al.	12-11-1990			
	4,981,873	514	562 Witte, et al.	01-01-1991			
	4,992,421	514	/ Q De	02-12-1991			
	5,338,755	514	414 Wagnon, et al.	08-16-1994			
	5,362,902	560	Barnish, et al.	11-08-1994			
	5,397,801	514	418 Wagnon, et al.	03-14-1995			
	5,481,005	548	537 Wagnon, et al.	01-02-1996			
	5,578,633	514	4/8 Wagnon, et al.	11-26-1996			
	5,650,428	514	414 Ohmori, et al.	07-22-1997			
	5,688,913	530	330 Arrhenius, et al.	11-18-1997			
	6,001,809	514	15 Thorsett et al.	12/14/1999			
	6,093,696	514	Head et al.	07/25/2000			
	6,110,945	514	332 Head et al.	08/29/2000			
	6,197,794	514	Head et al.	02/06/2001			
	6,221,888	514	357 Durette, et al.	04-24- 2001			
XXI	6,229,011	544	[17] Chen et al.	05/08/2001			
	6,239,108	514	15 Lin et al.	05/29/2001			

RECEIVED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 draw line through citation if not in conformance and not considered. Include copy of this form with next conformance and not applicant. SEND TO: Assistant Comprissioner for Patents, Washington, D.C. 20231.

FEB 2 7 2003 E

SHEET 2 OF 6

INFORMATION DESCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

ATTORNEY'S DKT NO. APPLICATION NO. 002010-603 09/127,364

APPLICANT Yednock, et al. Filing Date GROUP July 31, 1998 1653

6,248,713 5 4 00				July 31, 1998	1653
6,265,572 5 4 4 5 5 Chen et al. 07/24/2001 6,272,577 7	-01		classy	subclass	
6,272,577 710 110 Brown et al. 08/14/01 6,274,577 51 4 22 1 Brown et al. 08/14/2001 6,288,267 560 144 Hull et al. 09/11/2001 6,306,840 514 108 Adams et al. 10/23/2001 6,329,362 514 108 Achribald et al. 12/11/2001 6,329,372 514 24 Head et al. 12/11/2002 6,329,372 514 24 Head et al. 02/19/2002 6,369,229 514 342 Head et al. 03/26/2002 6,369,229 546 264 Head et al. 04/09/2002 6,369,229 546 264 Head et al. 04/09/2002 6,376,538 514 466 Adams et al. 04/30/2002 6,380,387 544 311 Sidduri et al. 04/30/2002 6,388,084 546 271 Kaplan et al. 05/14/2002 6,403,608 514 10 Dressen et al. 06/11/2002 6,403,608 514 10 Dressen et al. 06/11/2002 6,420,600 56 2 575 Sidduri et al. 07/16/2002 6,423,688 514 17 Thorsett et al. 07/23/2002 6,423,728 514 357 Hull et al. 07/23/2002 6,426,348 514 256 Hull et al. 07/23/2002 6,435,539 514 367 Hull et al. 09/24/2002 6,435,539 514 367 Hull et al. 09/24/2002 6,435,539 514 367 Hull et al. 09/24/2002 6,435,638,844 514 597 Hull et al. 09/24/2002 6,438,844	\(\frac{1}{2}\)	6,248,713	514	002 Lin et al.	06/19/2001
6,274,577 5 4 22 Brown et al. 08/14/2001 6,288,267 5 0 14		6,265,572	540	453 Chen et al.	07/24/2001
6,288,267 5 6 0 14 Hull et al. 09/11/2001 6,306,840 5 14 10 Adams et al. 10/23/2001 6,329,362 5 14 18		6,272,577	710	IIO Brown et al.	08/14/01
6,306,840 6,329,362 5 4		6,274,577	514	221 Brown et al.	08/14/2001
6,329,362 5 4 18		6,288,267	560	149 Hull et al.	09/11/2001
6,329,372 5 4 24 Head et al. 12/11/200		6,306,840	514	109 Adams et al.	10/23/2001
6,348,463 514 24 Head et al. 02/19/2002 5 6,362,204 514 342 Head et al. 03/26/2002 6 6,362,204 514 342 Head et al. 04/09/2002 6 6,369,229 546 264 Head et al. 04/09/2002 6 6,376,538 514 466 Adams et al. 04/23/2002 6 6,380,387 544 311 Sidduri et al. 04/23/2002 6 6,388,084 546 291 Kaplan et al. 05/14/2002 6 6,403,608 514 309 Langham et al. 06/11/2002 6 6,407,066 514 19 Dressen et al. 06/11/2002 6 6,407,066 514 19 Dressen et al. 06/18/2002 6 6,420,600 562 575 Sidduri et al. 07/16/2002 6 6,423,688 514 19 Thorsett et al. 07/23/2002 6 6,423,728 514 357 Hull et al. 07/23/2002 6 6,423,728 514 256 Hull et al. 07/23/2002 6 6,426,348 514 19 Ashwell et al. 07/23/2002 6 6,436,904 514 1 Ashwell et al. 09/24/2002 6 6,455,550 514 341 Chen et al. 09/24/2002 6 6,458,844 514 594 Hull et al. 10/01/2002 6 6,458,844 514 594 Hull et al. 10/01/2002 6 6,458,844 514 594 Hull et al. 10/01/2002 6 6,0032,786 USA 93-21-1997 USA 93-21-1997 USA 93-21-1997 USA 93-21-1997 USA 95-29-1997	N/K	6,329,362	514	188 Achribald et al.	12/11/2001
6,362,204 514 342 Head et al. 03/26/2002 6,369,229 546 264 Head et al. 04/09/2002 6,376,538 514 466 Adams et al. 04/23/2002 52 6,376,538 514 466 Adams et al. 04/23/2002 52 6,388,0387 544 311 Sidduri et al. 04/30/2002 52 6,388,084 546 241 Kaplan et al. 05/14/2002 6,403,608 514 304 Langham et al. 06/11/2002 6,407,066 514 14 Dressen et al. 06/11/2002 6,420,600 562 575 Sidduri et al. 07/16/2002 6,423,688 514 19 Thorsett et al. 07/23/2002 6,423,728 514 357 Hull et al. 07/23/2002 6,423,728 514 14 Ashwell et al. 07/30/2002 6,436,904 514 14 Ashwell et al. 07/30/2002 6,436,904 514 14 Ashwell et al. 08/20/2002 6,455,539 514 300 Langham et al. 09/24/2002 6,455,550 514 341 Chen et al. 09/24/2002 6,458,844 514 594 Hull et al. 10/01/2002 60/086,241 USA 63-21+1997 60/024,7890 USA 12-26-1996 60/047,856 USA 95-29-1997 60/048,017 USA 95-29-1997 60/048,017 USA 95-29-1997 97 60/066,787 USA 11-25-1997 97 60/066,787 USA 11-25-1997 97 60/066,787 USA 11-25-1997 97 08/821,825 USA 03-21-1997 97 08/821,825 USA 03-21-1997		6,329,372			12/11/200
6,369,229 5 4 6 36 4 Head et al. 04/09/2002 6 6,376,538 5 1 4 4 6 6 Adams et al. 04/30/2002 6 6,388,084 5 4 6 29 1 Kaplan et al. 05/14/2002 6 6,403,608 5 1 4 3 0 4 Langham et al. 06/11/2002 6 6,407,066 5 1 4 1 9 Dressen et al. 06/18/2002 6 6,420,600 5 6 2 5 75 Sidduri et al. 07/16/2002 6 6,420,688 5 1 4 1 9 Thorsett et al. 07/23/2002 6 6,423,728 5 1 4 35 7 Hull et al. 07/23/2002 6 6,433,728 5 1 4 35 7 Hull et al. 07/23/2002 6 6,436,904 5 1 4 1 4 Ashwell et al. 07/23/2002 6 6,455,539 5 1 4 30 0 Langham et al. 09/24/2002 6 6,455,539 5 1 4 30 0 Langham et al. 09/24/2002 6 6,455,550 5 1 4 3 4 1 Chen et al. 09/24/2002 6 6,455,550 5 1 4 3 4 1 Chen et al. 09/24/2002 6 6,455,550 5 1 4 3 4 1 Chen et al. 09/24/2002 6 6,455,550 5 1 4 3 4 1 Chen et al. 09/24/2002 6 6,455,550 5 1 4 3 4 1 Chen et al. 09/24/2002 6 6,455,550 5 1 4 3 5 9 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		6,348,463	514	24 Head et al.	02/19/2002
6,376,538 5 4		6,362,204		342 Head et al.	03/26/2002
6,376,538 5 4 466 Adams et al. 04/23/2002 5 6,380,387 544 3 Sidduri et al. 04/30/2002 5 6,388,084 546 241 Kaplan et al. 05/14/2002 5 6,403,608 5 4 3 04 Langham et al. 06/11/2002 6,407,066 5 4 1 Dressen et al. 06/18/2002 6,420,600 5 6 2 5 75 Sidduri et al. 07/16/2002 6,423,688 5 4 1 Thorsett et al. 07/23/2002 6,423,728 5 4 35 7 Hull et al. 07/23/2002 6,436,348 5 4 256 Hull et al. 07/23/2002 6,436,904 5 4 4 Ashwell et al. 08/20/2002 6,455,539 5 4 300 Langham et al. 09/24/2002 6,458,844 5 4 5 4 5 4 Hull et al. 09/24/2002 6,458,844 5 4 5 4 5 4 Hull et al. 10/01/2002 60/022,890 USA 07-25-1996 USA 07-25-1996 USA 07-25-1996 USA 05-29-1997 08/0047,954 USA 05-29-1997 08/0048,017 USA 05-29-1997 08/0048,017 USA 05-29-1997 08/0048,017 USA 05-29-1997 08/0046,023 USA 05-29-1997 08/0046,023 USA 03-21-1997 USA 03-21-1997 08/0046,023 USA 03-21-1997 USA 03-21-1997 08/0046,023 USA 03-21-1997 USA		6,369,229	546	264 Head et al.	04/09/2002
6,388,084 546 241 Kaplan et al. 05/14/2002 8 6,403,608 5 4 3 0 4 Langham et al. 06/11/2002 6,407,066 5 4		6,376,538	514	466 Adams et al.	
6,388,084 5 4 6 2 11 Kaplan et al. 05/14/2002 8 6,403,608 5 4 3 0 4 Langham et al. 06/11/2002 6,407,066 5 4 1	XX	6,380,387	544	311 Sidduri et al.	04/30/2002
6,403,608 5 4 3 04 Langham et al. 06/11/2002 6,407,066 5 4 1		6,388,084	546	291 Kaplan et al.	
6,420,600 562 575 Sidduri et al. 07/16/2002 6,423,688 514 19 Thorsett et al. 07/23/2002 6,423,728 514 357 Hull et al. 07/23/2002 6,426,348 514 256 Hull et al. 07/30/2002 6,436,904 514 14 Ashwell et al. 08/20/2002 6,436,904 514 30 Langham et al. 09/24/2002 6,455,539 514 30 Langham et al. 09/24/2002 6,455,550 514 341 Chen et al. 09/24/2002 6,458,844 514 594 Hull et al. 10/01/2002 6,6458,844 514 594 Hull et al. 10/01/2002 6,60/086,241 USA 63-21-1997 6,60/032,786 USA 12-06-1996 6,60/047,856 USA 05-29-1997 6,60/047,954 USA 05-29-1997 6,60/047,954 USA 05-29-1997 6,60/048,017 USA 05-29-1997 6,60/066,525 USA 11-25-1997 6,60/066,787 USA 11-25-1997 6,60/066,831 USA 11-25-1997 1,70/10,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,70/20,7		6,403,608	514	309 Langham et al.	
6,423,688 514 19 Thorsett et al. 07/23/2002 6,423,728 514 357 Hull et al. 07/23/2002 6,426,348 514 256 Hull et al. 07/30/2002 6,436,904 514 19 Ashwell et al. 08/20/2002 6,455,539 514 300 Langham et al. 09/24/2002 6,455,550 514 341 Chen et al. 09/24/2002 6,458,844 5 14 599 Hull et al. 10/01/2002 6,0086,241 USA 93-21-1997 60/022,890 USA 12-06-1996 60/047,954 USA 05-29-1997 60/047,954 USA 05-29-1997 60/048,017 USA 05-29-1997 60/066,321 USA 11-25-1997 60/066,831 USA 11-25-1997 08/821,825 USA 03-21-1997		6,407,066	514	Dressen et al.	06/18/2002
6,423,728 5 4 357 Hull et al. 07/23/2002 6,426,348 5 4 256 Hull et al. 07/30/2002 6,436,904 5 4 4 Ashwell et al. 08/20/2002 6,436,904 5 4 4 Ashwell et al. 09/24/2002 6,455,539 5 4 30		6,420,600	562	575 Sidduri et al.	07/16/2002
6.426,348 5 4 256 Hull et al. 07/30/2002 6.436,904 5 4 Ashwell et al. 08/20/2002 6.455,539 5 4 300 Langham et al. 09/24/2002 6.455,550 5 4 5 4 5 4 1 1 1 1 1 1 1 1 1		6,423,688	514	19 Thorsett et al.	07/23/2002
6,436,904 5 4 Ashwell et al. 08/20/2002 6,455,539 5 4 300 Langham et al. 09/24/2002 6,455,550 5 4 34 Chen et al. 09/24/2002 6,458,844 5 4 5 4 Hull et al. 10/01/2002 6,0/086,241 USA 63-21-1997 60/022,890 USA 12-06-1996 60/047,856 USA 05-29-1997 60/048,017 USA 05-29-1997 60/066,525 USA 11-25-1997 60/066,831 USA 11-25-1997 08/821,825 USA 03-21-1997	V	6,423,728	514		07/23/2002
6,455,539 5 4 300 Langham et al. 09/24/2002 6,455,550 5 4 5 9 Hull et al. 10/01/2002 6,458,844 5 4 5 9 Hull et al. 10/01/2002 60/086,241 USA 93-21-1997 60/022,890 USA 97-25-1996 60/032,786 USA 12-06-1996 60/047,856 USA 05-29-1997 60/048,017 USA 05-29-1997 60/048,017 USA 11-25-1997 60/066,525 USA 11-25-1997 60/066,831 USA 11-25-1997 08/821,825 USA 03-21-1997	DX.	6,426,348	514	256 Hull et al.	07/30/2002
6,455,550 5 4 34 Chen et al. 09/24/2002 6,458,844 5 4 5 9 Hull et al. 10/01/2002 60/086,241 USA 93-21-1997 60/022,890 USA 97-25-1996 C60/032,786 USA 12-06-1996 C60/047,856 USA 05-29-1997 C60/048,017 USA 05-29-1997 C60/066,525 USA 11-25-1997 C60/066,831 USA 03-21-1997	WY	6,436,904	514	Ashwell et al.	08/20/2002
6,458,844 5 4 5 9 Hull et al. 10/01/2002 -60/086,241 USA 63-21-1997 -60/022,890 USA 07-25-1996 -60/032,786 USA 12-06-1996 -60/047,856 USA 05-29-1997 -60/047,954 USA 05-29-1997 -60/048,017 USA 05-29-1997 -60/066,525 USA 11-25-1997 -60/066,831 USA 11-25-1997 -60/066,831 USA 11-25-1997 -60/066,831 USA 11-25-1997 -60/066,831 USA 03-21-1997	DX.	6,455,539	514	300 Langham et al.	09/24/2002
✓ 60/086,241 USA 03-21-1997 ✓ 60/022,890 USA 07-25-1996 ✓ 60/032,786 USA 12-06-1996 ✓ 60/047,856 USA 05-29-1997 ✓ 60/048,017 USA 05-29-1997 ✓ 60/066,525 USA 11-25-1997 ✓ 60/066,787 USA 11-25-1997 ✓ 60/066,831 USA 11-25-1997 ✓ 08/821,825 USA 03-21-1997	Note !	6,455,550	514	34 Chen et al.	09/24/2002
60/086,241 USA 63-21-1997 ★ 60/022,890 USA 67-25-1996 ★ 60/032,786 USA 12-06-1996 ★ 60/047,856 USA 05-29-1997 ★ 60/047,954 USA -05-29-1997 ★ 60/048,017 USA -11-25-1997 ★ 60/066,525 USA -11-25-1997 ★ 60/066,831 USA -11-25-1997 ★ 60/066,831 USA 03-21-1997 ★ 08/821,825 USA 03-21-1997	XX	6,458,844	514	599 Hull et al.	10/01/2002
X 60/032,786 USA 12-06-1996 X 60/047,856 USA 05-29-1997 X 60/047,954 USA 05-29-1997 X 60/048,017 USA 05-29-1997 X 60/066,525 USA 11-25-1997 X 60/066,787 USA 11-25-1997 X 60/066,831 USA 11-25-1997 X 08/821,825 USA 03-21-1997	\times	-60/086,24 1		USA	03 21 1997
X 60/047,856 USA 05-29-1997 X 60/047,954 USA 05-29-1997 X 60/048,017 USA 05-29-1997 X 60/066,525 USA 11-25-1997 X 60/066,787 USA 11-25-1997 X 60/066,831 USA 11-25-1997 X 08/821,825 USA 03-21-1997	\times	6 0/022,890		USA	0 7-25-199 6
\$60/047,954 USA 05 29 1997 \$60/048,017 USA 05-29-1997 \$60/066,525 USA	×	60 /032,78 6		USA	12-06-1996 -
\$\sqrt{60/048,017}\$ USA \text{05-29-1997}\$ \$\sqrt{60/066,525}\$ USA \text{11-25-1997}\$ \$\sqrt{60/066,787}\$ USA \text{11-25-1997}\$ \$\sqrt{60/066,831}\$ USA \text{11-25-1997}\$ \$\sqrt{08/821,825}\$ USA \text{03-21-1997}\$	×	6 0/047,856		USA	0 5-29-199 7
★ 60/066,525 USA 11-25-1997 ★ 60/066,787 USA 11-25-1997 ★ 60/066,831 USA 11-25-1997 ★ 08/821,825 USA 03-21-1997	X	60/047,954		USA	05-29-1997
\$\sqrt{60/066,787}\$ USA 11-25-1997 \$\sqrt{60/066,831}\$ USA 11-25-1997 \$\sqrt{08/821,825}\$ USA 03-21-1997	×			USA	0 5-29 -1 997-
Solve Solv	X	60/066,525		USA	11-25-1997
7 08/821,825 USA 03-21-1997	X	60/066.787		USA	11-25-1997
	X	60/066,831		USA	11-25-1997
	7	08/821,825		USA	03-21-1997
	•	/) A		
		(1)	<u> </u>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation If not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

FEB 2 7 2013

SHEET 3 OF 6

ATTORNEY'S DKT NO. APPLICATION NO. 002010-603 09/127,364

APPLICANT Yednock, et al.

FILING DATE GROUP July 31, 1998 1653

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

g. V. Sah		FODE	ICNSPATENT DOCUMEN	ÑTS	Sale of the sale o	
<u> </u>		nt Document	I O COLOR DE LA CO	NATION OF THE SECOND PROPERTY OF THE SECOND P		8 - 1984 CA
Examiner		Kind Code		Date of Publication	Trans	latio
Initials	Number	(if known)	Country	(MM-DD-YYYY)	Yes no	
	92/16549		WIPO	10-01-1992		
	94/07815		WIPO	04-14-1994		
	94/12181		WIPO	06-09-1994		
	95/15973		WIPO	06-15-1995		$\mathfrak{p}_{_}$
	96/01644		WIPO	01-25-1996	E [II
	96/20725		WIPO	07-11-1996	A C	1)
	96/20949		WIPO	07-11-1996 avi		III.
V	96/22966		WIPO	08-01-1996	2	\leq
00	97/03094		WIPO	01-30-1997 😤	003	Ш
XX	97/48726		WIPO	12-24-1997		P
i	98/04247		WIPO	02-05-1998		
	98/42656		WIPO	10-01-1998		
	98/53814		WIPO	12-03-1998		
	98/53817		WIPO	12-03-1998		Τ
	98/53818		WIPO	12-03-1998		T
	98/54207		WIPO	12-03-1998		
	98/58902		WIPO	12-30-1998		Τ
V	99/06432		WIPO	02-11-1999		o
1	99/06436		WIPO	02-11-1999		T
XX	99/10312		WIPO	03-04-1999		Γ
ì	99/10313		WIPO	03-04-1999		
<u> </u>	99/67230		WIPO	12-29-1999		T
	6147073		Australia	04-17-1975		\top
	23 57 334		Germany	06-06-1974		
	26 55 636		Germany	06-23-1977		T
	0 526 348		EPO	02-03-1993	T	T
	9714314.3		Great Britain	07-07-1997	1	T
	9714316.8		Great Britain	07-07-1997		
	9714335.8		Great Britain	07-07-1997		
	9711143.9		Great Britain	05-30-1997		T
	9722674.0	<u> </u>	Great Britain	10-27-1997		Π
00	9800680.2		Great Britain	01-14-1998	1	T
XX	9800684.4	1	Great Britain	01-14-1998	1	T

EXAMINER: Initial if reference considered, whether or not firstion is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

(05/01)

•		(o),	- 2013				SHEE.	T_4_(חב ה
Substitute for	form 1449A/PTO	FER 2	7 2003 🚉	ATTORNEY'S DK	τ No.	APPLICA	TION NO		7 0
\			`a\	002010-603 (APPLICANT		09/127	364		
INFORMATION DISCLOSUME STATEMENT BY APPEICANT		TC NUM	Yednock, et al.		GROUP	급			
SIA	ALEMENI	BY APPE	TCANI	July 31, 1998		1653	£		_;;
							ெ	MAR	
	9800686.9			Britain	· · · · · · · · · · · · · · · · · · ·	14-1998	NTER	0	ì
 	04 154732		† 	pan		05-27-1992		2	=
No-	06 016625 08 073422			pan		25-1994	600/	003	m
XX.	08 073422		Ja	pan	03-1	19-1996	2900		Q
	A A COLOR DE LA CO	NO	I	TURE DOCUMENTS	en de de creek andere Zeel daarde en de ee	Tarter garage Landa Arca	层V435 (%)		r i
Examiner Initials	Includ item (boo	e name of author	(in CAPITAL LETTE nal, serial, symposi	RS), title of the artium, catalog, etc.), d	cle (when app ate, page(s), v	ropriate), t	itle of t	he	Mind Mak
Indias I	ARCHIBALD.	S.C. et al		d/or country where p Evaluation of Po		ine_Rased	~4B1	Integr	rin
W	Antagonists", I	Bioorg & Med.	Chem. Lett., V	ol. 10, pp. 997-9	999 (2000).	inc-Dasco	ичрі	meg	1111
Ì	CRÓSSLEY, M Arthritis in BA	M.J., et al. "S LB/c Mice."	tudies on the Ef	fects of Pharmac in. Res. XIII(5):	ological Ag 273-277 (1	gents on A	Antige	n-Indu	ced
							of VL	Α-4 (α	4 B 1
	DUTTA, A.S., et al. "Potent Cyclic Monomeric and Dimeric Peptide Inhibitors of VLA-4 (α4β1 Integrin)-Mediated Cell Adhesion Based on the Ile-Leu-Asp-Val Tetrapeptide." <i>J. Peptide Sci.</i> 6: 321-341 (2000).								
	EL-NAGGAR,	A.M., et al.,	Acta. Pharm. Ji	ugosl. (1985), 35	5(1), 15-22.				-
SK	ENGLEMAN, V.W., et al. "Cell Adhesion Integrins as Pharmaceutical Targets." Ann. Reports in Med. Chem. 31: 191-200 (1996).								
	EWENSON, A. et al., "Analogues of Substance P Containing an α-hydroxy, β-amino acid: Synthesis and Biological Activity", Eur. J. Med. Chem., Vol. 26, pp. 435-442 (1991).								
	FOTOUHI, N., et al., "The Design and Synthesis of Potent Cyclic Peptide VCAM-VLA-4 Antagonists Incorporating an Achiral Asp-Pro Mimetic", <i>Bioorg & Med. Chem. Lett.</i> , Vol. 10, pp. 1171-1173 (2000).								
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	HAUBNER, R., et al. "Cyclic RGD Peptides Containing β-Turn Mimetics." J. Am. Chem. Soc. 118: 7881-7891 (1996).								
SA	HAUPTMANN, J., et al. "Degradation of a Benzamidine-Type Synthetic Inhibitor of Coagulation Enzymes in Plasma of Various Species." <i>Thrombosis Research</i> . 61: 279-284 (1991).								
	HAWORTH, D., et al. "Anti-inflammatory activity of c(ILDV-NH(CH ₂) ₅ CO), a novel, selective, cyclic peptide inhibitor of VLA-4-mediated cell adhesion." <i>Br. J. Pharmacol.</i> 126: 1751-1760 (1999).								
	JACKSON, D.Y., et al., "Potent α4β1 Peptide Antagonists as Potential Anti-Inflammatory Agents", J. Med. Chem., Vol. 40, pp. 3359-3368 (1997).								
	KATO, Y., et al., "Oxidative Degradation of Collagen and Its Model Peptide by Ultraviolet Irradiation", J. Agric. Food Chem., Vol. 40, pp. 373-379 (1992).								
$\propto \sim 1$	KOMORIYA, A., et al. "The Minimal Essential Sequence for a Major Cell Type-specific Adhesion Site (CS1) within the Alternatively Spliced Type III Connecting Segment Domain of Fibronectin Is Leucine-Aspartic Acid-Valine." J. Biol. Chem. 266(23): 15075-15079 (1991).								
	De Lul	fon	1/5/	04					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

FEB 2 7 2803

INFORMATION DEGLESURE STATEMENT BY APPLICANT

SHEET 5 07 6

ATTORNEY'S DKT NO. 09/127,004

APPLICANT
Yednock, et al.

FILING DATE GROUP
July 31, 1998

SHEET 5 07 6

APPLICATION NO. 09/127,004

APPLICANT
Yednock, et al.

	6 0
De	KUDLACZ, E., et al., "Pulmonary Eospinophilia in a Murine Model of Allergic Inflation is Attenuated by Small Molecule α4β1 Antagonists", <i>J. of Pharm and Exp. Ther.</i> , Vol. 38 No. 2, pp. 747-752.
	KUROKAWA, M., et al. "Synthesis and Antiinflammatory Activity of <i>cis</i> - and <i>trans</i> -6,6a,7,8,9,10,10a,11-Octahydro-11-oxodibenzo[b,e]thiepinacetic and -oxepinacetic Acids." J. Med. Chem. 33: 504-509 (1990).
	LEIBFRITZ, D., et al., Tetrahedron (1982), 38(14), 2165-81.
	LIN, K., et al., "Selective, Tight-Binding Inhibitors of Integrin α4β1 that Inhibit Allergic Airway Responses", J. Med. Chem., Vol. 42, pp. 920-934.
	MÜLLER, G., et al., "Discovery and Evaluation of Piperidinyl Carboxylic Acid Derivatives as Potent $\alpha_4\beta_1$ Integrin Antagonists", <i>Bioorg. & Med. Chem. Lett.</i> , ol. 11, pp. 3019-3021 (2001).
	PAPAIOANNOU, D., et al., "Facile Preparation of the 1-Hydroxybenzotriazolyl Ester of N-Tritylpyroglutamic Acid and its Application to the Synthesis of TRH, [D-His ²]TRH and Analogues Incorporating cis- and trans-4-Hydroxy-L-Proline", Acta Chem. Scand., Vol. 49, pp. 103-114 (1995).
X	PERI, F., et al., "Assembly of Binding Loops on Aromatic Templates as VCAM-1 Mimetics", J. of Peptide Sci., Vol. 5, pp. 313-322 (1999).
	SIMANIS, V. et al., Int. J. Pept. Protein Res. (1982), 19(1), 67-70.
	SOUERS, A.J., et al., "Novel Inhibitors of α4β1 Integrin Receiptor Interactions Through Library Synthesis and Screeing", <i>Bioorg. & Med. Chem. Lett.</i> , Vol. 8, pp. 2297-2302 (1998)
	TAIT, A., et al. "Synthesis and Antiinflammatory Activity of 2,6-Bis(1,1-Dimethylethyl)Phenol Derivatives." <i>Il Farmaco</i> . 48(10): 1463-1473 (1993).
	UREN, M.F., et al. "The Effect of Anti-Inflammatory Agents on the Clinical Expression of Bovine Ephemeral Fever." <i>Veterinary Microbiology</i> . 19: 99-111 (1989).
V	van der Laan, LJW, et al., "Beneficial Effect of Modified Peptide Inhibitor of α4 Integrins on Experimental Allergic Encephalomyelitis in Lewis Rats", J. of Neurosci. Res., Vol. 67, pp. 191-199 (2002).
XX	VATISTAS, N.J., et al. "Infection of the intertubercular bursa in horses: four cases (1978-1991)." J. Am. Vet. Med. Assoc. 208(9): 1434-1437 (1996).
	VOIGT, B., et al. "Synthese von Nα-(Arylsolfonyl-L-prolyl)-und Nα-Benzyloxycarbonyl-L-prolyl)-D,L-4-amidinophenyl-alaninamiden als Thrombininhibitoren." <i>Pharmazie</i> . 41: 233-235 (1986).
	YANG, Y., et al. "LPAM-1 (integrin α4β7)-ligand binding: overlapping binding sites recognizing VCAM-1, MadCAM-1 and CS1 are blocked by fibrinogen, a fibronectin-like polymer and RGD-like cyclic peptides." <i>Eur. J. Immunol.</i> 28: 995-1004 (1998).
	Chemical Abstract No. 126040, Vol. 74, No. 23 (June 7, 1971).
\\	Chemical Abstract No. 176262, Vol. 99, No. 21 (November 21, 1983).
	Chemical Abstract No. 210288, Vol. 106, No. 25 (June 22, 1987).
XX	Chemical Abstract No. 167952, Vol. 108, No. 19 (May 9, 1988).

EXAMINER: Initial if reference considered, whether or not situation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

,	MPE				
•	\0. \ <i>i\</i>			SHEET	6 OF <u>6</u>
Substitute for form 1449A/PTO	FEB 2 7 2003 💆	ATTORNEY'S DK 002010-603		PLICATION NO.	
INFORMATION DICC	\ #I	APPLICANT	1 09	/127,364	
INFORMATION DISC	LOS UKE NO	Yednock, et al.			
STATEMENT BY APP	PLICANT	FILING DATE July 31, 1998		OUP 553	
_0					
Chemical Abstract No. 34	164, Vol. 125, No.	3 (July 15, 199	6).		
Chemical Abstract No. 21	1689, Vol. 117 (1992	2) Gamo.			
Examiner Signature		Date Considered			,
David Ly	Land	1/5	104	TECHCENTER	RECEIVED NO.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.